Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by AAVantgarde
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
Today 7:00 EST
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 08, 2026
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
November 03, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting
October 07, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
October 02, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025
September 05, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025
August 28, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
August 12, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
July 15, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting
May 12, 2025
From
AAVantgarde
Via
GlobeNewswire
AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer
April 28, 2025
From
AAVantgarde
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.